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Background: High density lipoproteins (HDL) protect against cardiovascular disease (CVD). However, increased 
serum amyloid-A (SAA) related inflammation may negate this property. This study investigated if SAA was 
related to CVD-burden.  
Methods: Subjects referred to the rapid chest pain clinic (n=240) had atherosclerotic burden assessed by cardiac 
computerised tomography angiography. Subjects were classified as: no-CVD (n=106), non-obstructive-CVD, 
stenosis<50% (n=58) or moderate/significant-CVD, stenosis≥50% (n=76). HDL was subfractionated into HDL2 
and HDL3 by rapid-ultracentrifugation. SAA-concentration was measured by ELISA and lecithin cholesterol 
acyltransferase (LCAT) activity measured by a fluorimetric assay.  
Results: We illustrated that serum-SAA and HDL3-SAA-concentration were higher and HDL3-LCAT-activity 
lower in the moderate/significant-CVD-group, compared to the no-CVD and non-obstructive-CVD-groups 
(percent differences: serum-SAA, +33% & +30%: HDL3-SAA, +65% and +39%: HDL3-LCAT, -6% & -3%; 
p<0.05 for all comparisons). We also identified a positive correlation between serum-SAA and HDL3-SAA 
(r=0.698;p<0.001) and a negative correlation between HDL3-SAA and HDL3-LCAT-activity (r=-0.295;p=0.003), 
while CVD-burden positively correlated with serum-SAA (r=0.150;p<0.05) and HDL3-SAA (r=0.252;p<0.001) 
and negatively correlated with HDL3-LCAT-activity (r=-0.182;p=0.006). Additionally, multivariate regression 
analysis adjusted for age, gender, CRP and serum-SAA illustrated that HDL3-SAA was significantly associated 
with modifying CVD-risk of moderate/significant CVD-risk (p<0.05). 
Conclusion: This study has demonstrated increased SAA-related inflammation in subjects with 
moderate/significant CVD-burden, which appeared to impact on the antiatherogenic potential of HDL. We suggest 
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It has become increasingly apparent that chronic inflammation plays a major role in the development of 
cardiovascular disease (CVD)[1,2] and it is clear that established risk factors do not fully explain its development. 
As a consequence there is increasing interest in the use of novel biochemical markers for the assessment of 
atherosclerosis and the prediction of cardiovascular risk. Many cytokines and chemokines have been implicated 
in promoting various stages of the atherosclerotic process, including interleukin (IL)-1, IL-2, IL-6, tumour 
necrosis factor α (TNF-α), interferon-γ and monocyte chemo-attractant protein-1 (MCP-1). Some of these primary 
signalling molecules are released from activated immune cells, such as macrophages; in response to endothelial 
damage early in the atherosclerotic process. The release of chemokines attracts macrophages and platelets, while 
the pro-inflammatory cytokines induce proliferation and differentiation of immune cells and smooth muscle cells. 
Eventually, sufficiently elevated cytokine levels may lead to systemic effects, with several plasma inflammatory 
biomarkers being measureable, including C-reactive protein (CRP)[3] and serum amyloid A (SAA)[4]. 
Although the protective role of high density lipoproteins (HDL) against the development of CVD is well 
established[5,6], this role may be diminished when SAA associates with this lipoprotein. This association alters 
the physicochemical properties of HDL[7], particularly the smaller HDL subfraction, HDL3[8], causing it to 
become dysfunctional. Dysfunctional HDL binds to proteoglycans on the vascular wall, favouring their retention 
and modification by the vascular matrix. It also enhances cholesterol ester uptake into macrophages and reduces 
reverse cholesterol transport (RCT)[9,10], as demonstrated by the ex vivo and in vitro experiments of Heinecke’s 
group[11]. Dysfunctional HDL induces the release of pro-inflammatory cytokines[12], enhances the recruitment 
of monocytes into vascular plaques[13] and causes macrophage accumulation[14], thus helping propagate the 
inflammatory process. Furthermore, SAA impairs the antioxidant function of HDL[15], while the activity of HDL 
remodelling enzymes, such as lecithin cholesterol acyltransferase (LCAT), an enzyme that is responsible for the 
esterification of free cholesterol within HDL3 and thus its maturation to HDL2, is reduced by the presence of 
SAA[16]. However, the role of LCAT in the atherosclerotic process remains discordant[17], as reviewed[18]. 
The presence of CVD may be assessed by cardiac computerised tomography angiogram (CCTA), which 
is an effective and non-invasive way to assess atherosclerotic burden in low to intermediate-risk patients[19]. 
However, the cost implications of CCTA may prohibit its widespread use. Therefore, the primary aim of this study 
was to assess if measuring SAA could indicate CVD-burden/presence and indicate more proatherogenic HDL, 
meaning that it could be used alongside CCTA or as a surrogate of CVD presence, if CCTA was unavailable. The 
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secondary aim was to assess if the LCAT in HDL2 and HDL3 was altered to a more proatherogenic phenotype in 
the presence of SAA, potentially increasing CVD-risk. These aims were examined in an adult population that had 
been referred for investigation with suspected ischaemic cardiac chest pain and who had CVD-burden classified 
by CT imaging and calcium scoring. 
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2. Methods and Materials 
Ethics was obtained from the Office for Research Ethics Committees for Northern Ireland (ID number: 
10/NIR01/51). 
2.1 Patient population 
The subjects for this cross-sectional study were enrolled in the Cardiac-CT for the Assessment of Pain and 
Plaque (CAPP)-Study (ISRCTN52480460), as previously described in detail[20]. In brief, these subjects had been 
referred for investigation with suspected ischaemic cardiac chest pain, without symptoms suggestive of unstable 
angina. Subjects (n=500), were assigned into one of two arms. In the first arm, CVD presence was assessed by 
conventional stress test (n=250), in the second arm, CVD burden was assessed by calcium scoring and CT imaging 
by CCTA (n=250). 
The current study utilised serum from the subjects randomised to the CT arm (n=250). Any subject defined 
as having an active infection (hsCRP >10,000 µg/L) were excluded from the analyses, in accordance with 
American Heart Association Guidelines[21]. A further 4 subjects withdrew, leaving a total population of 240 
subjects in this CT arm. These subjects were classified according to CVD-burden using the American Heart 
Association’s 15 point scale[22], which is a division of the coronary tree divided into 15 parts, multiplied by the 
severity of stenosis in each part. Subjects were assigned into one of the three groups according to the 
absence/presence of CVD: 1) no-CVD (n=106); 2) non-obstructive-CVD, area of stenosis <50% (n=58); 3) 
moderate/significant-CVD, area of stenosis >50%, minimum luminal area >4mm2 (n=76). Calcium scores (CS) 
were performed by a non-enhanced low radiation scan that produces a series of stacked transaxial images, which 
can allow an assessment of the volume of calcium present in a patient’s coronary arteries. 
Exclusion criteria 
Exclusion criteria were a history of contrast media reaction, previous known coronary disease, BMI >35 
kg/m2, tachyarrhythmia, impaired renal function with an estimate GFR <35 ml/min, uncontrolled hypertension 
>220/100 mmHg, severe peripheral vascular disease, left bundle branch block or any other clinical reason that 
attending the clinic might compromise the patient’s safety. 
2.2 Blood Processing 
Fasting blood was collected into standard serum tubes by the vacuette system. Serum was obtained by 
centrifugation at 3000 rpm for 15 minutes at 4oC and frozen at -80°C in 1.3 mL aliquots, until required for further 
analysis.  
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2.3 Primary Subject Analyses 
Baseline measurements included fasting serum total cholesterol, triglycerides, HDL cholesterol and LDL 
cholesterol and were measured using standard enzymatic assays on an automated ILab-600 biochemical analyser 
(Cobas Roche Diagnostics, West Sussex, UK). High sensitive C-reactive protein (hsCRP) was measured by an 
ELISA procedure using a commercial available kit (BioCheck Inc., Foster City, USA). Height (cm) and weight 
(kg) were collected using a stadiometer and calibrated scales, and used to determine BMI (kg/m2). 
2.4 Isolation of HDL2 and HDL3 from Serum 
HDL2 and HDL3 were isolated by rapid ultracentrifugation from freshly thawed serum according to the 
method of McPherson et al[23]. This involved a 3-step, 6-hour long procedure, whereby crude (c)HDL was 
isolated by rapid sedimentation ultracentrifugation (2-hours), followed by its subfractionation into HDL2 and 
HDL3 by 2 x 2-hour sequential rapid flotation ultracentrifugation procedures. HDL samples were then stored at -
80°C and batch analysed. 
Results are presented as both non-protein standardised and protein standardised. The non-protein standardised 
results illustrate the levels of biomarker (SAA and LCAT) in the sample as a whole, while the protein standardised 
result provide a surrogate marker of the level of biomarker (SAA and LCAT) in an individual HDL particle. 
2.5 Serum, HDL2 and HDL3-SAA 
The concentration of SAA was measured in serum, HDL2 and HDL3 by a commercially available ELISA 
procedure, which measures SAA-1 (Invitrogen, Human SAA KHA0011C). SAA was assessed on a Grifols 
TRITURUS automated ELISA system (Italy), as per the manufacturer’s instructions, with the following 
modifications: Serum was diluted 1:150, HDL2 was diluted 1:10 and HDL3 diluted 1:100 prior to analysis. The 
intra-assay CVs for serum-, HDL2- and HDL3-SAA were 2.8, 3.7 and 5.6%, respectively, while their inter-assay 
CVs were 8, 9.5 and 11%, respectively. Non-protein standardised results are presented as µg/L, which is the 
absolute concentration in the serum or in the HDL2 and HDL3 subfractions after isolation. In addition, SAA 
associated with HDL2 and HDL3 was also standardised for protein concentration and is presented as μg SAA/mg 
protein.  
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2.6 HDL2 and HDL3-LCAT Activity and Mass 
The activity of LCAT was measured by a fluorimetric procedure (RB-LCAT; Roar Biomedical, NY, US), 
as per the manufacturer’s instructions, using 5µL of either serum, HDL2 or HDL3. This assay was based on the 
ratio of the substrate reagent (phosphatidylcholine), which has two distinct peaks, 390nm and 470nm. The relative 
intensity of the peaks depends upon the concentration of the hydrolysed (390nm peak) and the non-hydrolysed 
(470nm peak) phosphatidylcholine. After hydrolysis of phosphatidylcholine by the source of LCAT (i.e. serum, 
HDL2 or HDL3 from the subject population) there was a shift in the emission spectrum, with an increase in the 
390nm emission at the expense of the 470nm emission peak. Results are expressed as a ratio of these emitters, the 
greater the ratio, the higher the LCAT activity.  
LCAT mass was measured by an ELISA procedure (E98516Hu-USC, Stratech, Suffolk, UK), following 
the manufacturer’s instructions, with the following dilutions: serum 1:4000; HDL2 1:2500; HDL3 1:3000. 
The intra-assay CVs for HDL2- and HDL3-LCAT activity were both <1.0%, while their inter-assay CVs 
were 4.4 and 1.0%, respectively. The intra-assay CVs for HDL2- and HDL3-LCAT mass were 11 and 4%, 
respectively, while their inter-assay CVs were 17 and 11%, respectively. LCAT mass was expressed as μg/L. 
2.4 Statistical Analysis 
Statistical analysis was performed using SPSS Statistics version 21.0. Variables were assessed for 
normality and logarithmically transformed where required. Results are reported as mean (standard deviation; SD) 
when normally distributed, as geometric mean (interquartile range; IQ) when normally distributed after 
logarithmic transformation. Trends across the groups were analysed by One-Way ANOVA with LSD (least 
significant difference) post hoc analyses to assess differences between groups. Correlations were assessed using 
Pearson’s correlation coefficient. The assessment of associations of covariates with CVD risk (which is defined 
as the presence of any CVD, compared to no CVD or significant CVD compared to no or mild CVD) was obtained 
using a logistic regression model. Age was included in the model as a continuous variable.  A value for the area 
under the ROC (receiver operator characteristics) curve (AUC), also known as the C statistic, was evaluated by 
using phenotypes with any symptoms of CVD vs. those with no-CVD. A method to compare the area under two 
ROC curves derived from paired measurements was used to assess the value of adding extra variables to the 
prediction equation[24], as a measure of overall diagnostic performance (95% confidence intervals; CI). Four 
models were used: model 1-gender; model 2-age; model 3-gender+age; model 4-gender+age+HDL3-SAA. 
Significance was set as p≤0.05 for all analyses.  
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3. Experimental Results 
3.1 Subject characteristics according to CVD-burden 
Subject characteristics have previously been described[20]. However, for completeness they are included 
in table 1, where BMI, triglycerides and LDL-cholesterol were comparable between the groups (p>0.05 for all 
trends across the groups). Age significantly increased in line with CVD-burden (p<0.001 for trend across the 
groups). There was also a gender difference between the groups (p<0.05 for trend across the groups). Specifically, 
there were fewer males in the group with no-CVD, compared to the two groups with documented CVD (p<0.001 
for both comparisons). Total cholesterol was also different across the groups, (p<0.05 for trend across the groups), 
which was driven by the significantly higher total cholesterol in the no-CVD group, compared to the group with 
moderate/significant-CVD (p=0.003). HDL-cholesterol was significantly different across the groups (p≤0.001 for 
trend across the groups), which was driven by the higher HDL-cholesterol in the group with no-CVD, compared 
to the two groups with documented CVD (p=0.005 and p=0.001, respectively). As expected and according to 
group assignment, area of stenosis increased across the groups (p<0.001 for trend across the groups), which was 
driven by the greater area of stenosis in the group with moderate/significant-CVD, compared to the other two 
groups (p<0.001 for both comparisons) and between the non-obstructive-CVD group and the no-CVD group 
(p<0.001). There was a similar trend for calcium scores (p<0.001 for trend across the groups). A similar number 
of subjects had type 2 diabetes, were smokers and were on hypertensive medications. However, statin therapy 
differed across the groups (p<0.001 for trends across the groups). In this case, statin therapy was significantly 
lower in the group with no-CVD, compared to the non-obstructive and moderate/significant-CVD groups 
(p=0.006 and <0.001, respectively). There was no difference in statin therapy between the two groups with 
documented CVD (p=0.271). 
3.2 Serum-hsCRP and serum-SAA concentration according to CVD-burden 
A positive relationship was identified between serum-hsCRP and serum-SAA (r=0.267, p<0.001). 
Although serum-hsCRP concentration was not influenced by CVD-burden (table 2; p>0.05 for trend across the 
groups), post hoc analyses revealed increased serum-hsCRP in the group with moderate/significant-CVD, 
compared to the group with no-CVD (p=0.049), but not between the two groups with documented CVD (p=0.620). 
However, serum-SAA was influenced by CVD-burden (table 2; p<0.05 for trend across the groups), where it was 
33% and 30% higher the group with moderate/severe-CVD, compared to the no-CVD and non-obstructive groups 
(p=0.02 and 0.05, respectively). Serum-SAA was not different between the no-CVD and non-obstructive-CVD 
groups (p=0.855). 
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HDL2 and HDL3-SAA concentration according to CVD-burden 
HDL2: Non-protein standardised HDL2-SAA was not related to CVD-burden (table 2; p>0.05 for trend across the 
groups). However, when HDL2-SAA was standardised to protein, we fund that its levels were related to CVD-
burden (table 2; p<0.05 for trends across the groups). Post-hoc analyses illustrated that this was related to the 58% 
increase in its levels in the group with moderate/severe-CVD, compared to the group with no-CVD (p=0.004). 
However, in spite of the protein standardised HDL2-SAA being 40% higher in the non-obstructive-CVD group, 
compared to the group with no-CVD, this only approached significance (p=0.064). There was no difference in 
protein standardised HDL2-SAA between the non-obstructive and moderate/significant-CVD groups (p=0.436). 
HDL3: HDL3-SAA was related to CVD-burden, whether non-protein standardised or protein standardised (table 
2; p<0.05 and p<0.001, respectively for trend across the groups). For the non-protein standardised HDL3-SAA, 
its concentration was 41% and 43% higher in the group with moderate/significant-CVD, compared to the no-CVD 
and non-obstructive-CVD groups (p=0.012 and 0.024, respectively). For the protein standardised HDL3-SAA, its 
concentration was 65% and 39% higher in the group with moderate/significant-CVD, compared to the no-CVD 
and non-obstructive-CVD groups (p=0.001 and 0.014, respectively). There was no difference between the no-
CVD and non-obstructive-CVD groups for both non-protein and protein standardised HDL3-SAA (p=0.961 and 
0.295, respectively). 
3.3 HDL2 and HDL3-LCAT activity and mass according to CVD-burden 
HDL2: the activity and mass of LCAT was not different across or between the groups (table 3: p>0.05 for both 
trends across the groups). 
HDL3: LCAT activity was related to CVD-burden (p<0.05 for trend across the groups), where its activity was 6% 
and 3% lower in the group with moderate/significant-CVD, compared to the no-CVD and non-obstructive groups 
(p=0.007 and 0.036, respectively). There was no difference in LCAT activity between the no-CVD and non-
obstructive-CVD groups (p>0.05). HDL3 LCAT mass was not different between the groups (table 3; p>0.05 for 
trend across the groups). 
Correlations between CVD-burden and SAA concentration and LCAT activity 
Serum: the concentration of SAA was positively correlated with HDL2 and HDL3-SAA (r=0.585, p<0.001: 
r=0.698, p<0.001, respectively. 
HDL2: the concentration of SAA was not related to the degree of CVD-burden or LCAT-activity (p<0.05 for both 
correlations).  
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HDL3: the concentration of SAA was positively correlated with the degree of CVD-burden (r=0.252, p<0.001) 
and negatively correlated with the activity of LCAT (r=-0.182, p=0.006). 
3.4 Multivariate and Receiver operator characteristic curve analyses 
The following covariates were associated with increased significant CVD risk compared to no CVD in a 
multivariate analysis also adjusted for CRP and serum-SAA (table 4): male gender (odds ratio (OR)=11.9; 
confidence interval (CI): 4.41-32.2; p<1x10-5), age (per year increase; OR=1.16; CI: 1.10-1.21; p<1x10-5), and 
HDL3-SAA (per 10-fold increase: OR=5.85; CI: 1.33-25.7; p=0.02). No evidence to support an interaction 
between any of the covariates within the regression model was found. 
Area under the ROC curves (AUC) (CI) illustrated that for model 1-gender, the AUC was 0.680 (0.608-
0.752, p<0.001): For model 2-age, the AUC was 0.724 (0.658-0.789, p<0.001): For model 3-gender+age, the 
AUC was 0.819 (0.764-0.874, p<0.001): For model 4-gender+age+HDL3-SAA, the AUC was 0.824 (0.769-0.879, 
p<0.001). These results illustrate that by adding HDL3-SAA to the model meant that our predictive power to 
illustrate the presence of CVD was improved to 82.4%, over that of gender (68.0%), age (72.4%) and gender+age 
(81.9%). We also reran these models with serum-SAA in the model instead of SAA-HDL3 and found a reduction 
in the size of the effect and significance of the association with any CVD. 
In addition, when we added HDL-cholesterol to the existing ROC curve, the new estimates were: 0.83 (0.776, 
0.884), indicating a slight but non-significant improvement in the AUC (p<0.05). Total cholesterol, triglyceride 
and LDL-cholesterol have no significant effect. Finally, we re-ran the regression models with LCAT activity 
included as a covariate and identified that LCAT activity did not contribute to the model. 
  




To the author’s knowledge this is the first cross-sectional study to examine the relationship between CVD-
burden, inflammation and compositional changes to the main subfractions of HDL, namely HDL2 and HDL3. The 
main findings were that inflammatory SAA was increased in serum and HDL3 which, in the case of HDL3 was 
moderately associated with increased risk of significant CVD, proving HDL3-SAA to be a sensitive biomarker of 
CVD-burden and indicating that inflammation was increased in subjects with documented CVD. In addition, the 
activity of HDL3-LCAT was also weakly influenced by the degree inflammation and CVD severity. We suggest 
that SAA may be useful prognostic tools in identifying patients with high atherosclerotic burden, and thus 
increased CVD-risk. 
Although the measurement of serum-hsCRP is established as a biomarker of CVD-risk, the current study 
was unable to identify such an association, although we did identify that hsCRP was significantly higher in the 
group with significant-CVD, compared to the no-CVD group (p=0.049). We, therefore, suggest that although 
hsCRP is the most extensively studied biomarker linked to the pathophysiology of atherosclerosis[25], it may only 
be at the advanced stages of CVD that it may be predicative. However, we were able to demonstrate that serum-
SAA was related to the degree of CVD-burden and that a strength of this study was the fact that none of our 
subjects were on lipid-lowering medication, especially statins, which are known to lower SAA[41], thus removing 
any confounding influence that these drugs may have displayed on our findings. Our findings are consistent with 
previous studies that have proposed serum-SAA as sensitive biomarker to illustrate increased inflammation[3,27-
28]. In the circulation, SAA rapidly associates with HDL, where it renders this lipoprotein dysfunctional with 
numerous proinflammatory actions[9-11], which include reduced antioxidant capacity[15] and reduced RCT 
capabilities[10]. Thus, as the current study was also able to demonstrate that the increase in serum-SAA 
augmented its association with HDL, particularly HDL3, the HDL subfraction more closely associated with 
SAA[8], this illustrates that HDL3 was potentially proatherogenic in the subjects with significant-CVD burden. 
This concept is driven by the documented proof that when HDL is associated with SAA it displays diminished 
antiatherogenic properties[11]. In further support of our findings, a recent publication by Zewinger et al[29] 
reported that SAA modified the biological effects of HDL-cholesterol in several clinical conditions. 
The current study also identified lower HDL3-LCAT activity in the subjects with increased CVD-burden, 
again indicating HDL3 subfractions with a more proatherogenic phenotype. Furthermore, as the mass of LCAT 
was not different between the groups, it would suggest that functional changes had occurred within this enzyme. 
This concept corroborates gene studies, where heterozygous carries of mutations in the LCAT gene display 
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reduced LCAT activity, concomitant with a reduction in HDL-cholesterol. Furthermore, reduced LCAT function 
has been associated with increased atherosclerosis, as measured by intimal media thickness[30]. This latter study 
also suggested that increasing LCAT activity may not only increase serum HDL-cholesterol, but also decrease 
inflammation in the form of hsCRP. This concept was supported, in part, by the current findings where 
inflammation, in the form of HDL3-SAA, was decreased in the subjects with increased HDL3-LCAT activity. This 
model was strengthened by the negative correlation identified between HDL3-LCAT activity and HDL3-SAA. 
However, evaluation of this relationship would require further investigation via a longitudinal study to fully 
explore the influence of CVD-burden and its impact on the activity of HDL-LCAT. This would be particular 
pertinent, as the protective role of LCAT in the development/progression of CVD is contested, as several studies 
have indicated that decreased LCAT activity and mass are not associated with cardio-protection[17] and does not 
predict adverse cardiac events, while others suggest that higher LCAT activity was associated with increased 
intima thickness and was a risk for CHD and sudden death. Furthermore, in the review by Frohlich’s group, who 
documented that in subjects with complete deficiency of LCAT, their increased atherosclerosis may be related to 
low LDL levels and not the lack of LCAT[18]. 
5. Study Limitations 
There are several limitations to the present study. Firstly, the cholesterol efflux abilities of HDL were not 
examined, which would definitively confirm if HDL had reduced RCT capabilities. Secondly, it was also 
interesting to note that addition of HDL3-SAA to our regression model did not significantly improve the area 
under the ROC curve, with only a moderate increase from 0.819 to 0.824 (a point of note: the P values quoted 
within the various models relates to the significance of the predictive value of the parameters included in the 
model and are not a reflection of the comparison between the models). Evaluation of risk prediction models 
requires the use of model performance measures, such as the popular ROC metric. Its probabilistic interpretation 
of its value is based upon the ability of the models’ predicted probabilities to correctly discriminate between 
randomly selected diseased and non-diseased participants. However, it is not uncommon for the area under the 
ROC curve to show only small and non-significant improvements, even for a predictor variable that makes a 
significant independent contribution in a logistic regression analysis. More recently, alternative methods for 
evaluating the usefulness of a new marker have been proposed, including event-specific reclassification tables 
and integrated (average) sensitivity, although these methodologies are more typically used in cohort rather than 
case-control studies.  




This study has provided moderate evidence that SAA differs according to the degree of CVD-burden, 
which was specifically applicable to HDL3-SAA following regression analysis and adjustment for other 
covariates. This finding confirms HDL3-SAA as a useful and sensitive biomarker of increased CVD and provides 
a means of assessing CVD-burden. Additionally, this study illustrated that increased CVD-burden impacted, 
although less strongly, on functional properties of HDL3, as shown by what could be proatherogenic changes to 
the activity of LCAT. This study adds to the existing portfolio of the importance of functional HDL to reduce 
CVD and establishes SAA as a candidate biomarker to aid in the diagnosis of CVD-burden. 
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Age (years) 53.8(8.8)a 56.8(8.6)b 64.6(9.5)c <0.001 
Gender (% Male) 40a 74b 72b <0.001 
BMI (kg/m2) 27.5(3.5) 27.6(3.9) 28.0(3.5) 0.576 
Total Chol (mmol/L) 5.54(1.09)a 5.30(1.16)ab 5.03(1.09)b 0.011 
Trigs (mmol/L) 1.33(0.76) 1.44(0.77) 1.48(0.86) 0.424 
LDL Chol (mmol/L) 3.32(0.96) 3.23(1.00) 3.00(0.95) 0.076 
HDL Chol (mmol/L) 1.64(0.50)a 1.42(0.42)b 1.39(0.45)b 0.001 
Area of Stenosis (AU) 0.00(0.00)a 2.79(1.95)b 12.28(7.82)c <0.001 
Calcium Scores (%) 0.00(0.00)a 45.91(34.58)b 70.18(24.51)c <0.001 
Lipid Lowering Therapy (n)  14a   18bc  30c <0.001 
ACE Inhibitor Therapy (n) 9 7 11 0.133 
T2DM (n) 3 3 7 0.203 
Smokers (n) 18 12 13 0.571 
Results expressed as mean(SD) or as geometric mean(interquartile range) if not normally distributed. Similar 
superscript letters indicate no differences between groups, and different superscript letters indicate differences 
between groups (significance set at p≤0.05). 
CVD; cardiovascular disease: BMI; body mass index: Chol; cholesterol: Trigs; triglycerides: LDL; low density 
lipoproteins: HDL; high density lipoprotein: Area of stenosis is expressed as arbitrary units (AU) and is 
evaluated by The American Heart Association’s 15-point scale[22], which is a division of the coronary tree 
divided in to 15 parts, multiplied by the severity of stenosis in each part. 
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Moderate/Significant-CVD (n=74) Oneway 
ANOVA 
Serum-hsCRP (µg hsCRP/L) 1900(630,2732) 2100(690,2884) 2380(961,3003) 0.270 
Serum-SAA (µg SAA/L) 16216(7452,23186)a 16675(7240,21146)a 21605(9468,25651)b 0.046 
HDL2-SAA (μg SAA/L) 1278(445,1826) 1208(408,1789) 1632(465,2204) 0.121 
HDL2-SAA (μg SAA/mg protein) 3.59(1.61,5.56)a 5.03(2.83,6.24)a,b 5.67(2.58,6.96)b,c 0.012 
HDL3-SAA (μg SAA/L) 11748(5054,17237)a 11648(4407,16314)a 16614(7193,17640)b 0.016 
HDL3-SAA (μg SAA/mg protein) 2.69(1.37,3.73)a 3.19(1.31,4.60)a,b 4.44(1.88,5.38)c <0.001 
Results expressed as mean(SD) or as geometric mean(interquartile range) if not normally distributed. Similar superscript letters indicate no differences between groups, 
different superscript letters indicate differences between groups (significance set at p≤0.05). 
CVD; cardiovascular disease: hsCRP; high sensitive C-reactive protein: SAA; serum amyloid A: HDL; high density lipoprotein.  
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LCAT Activity     
HDL2 (ratio) 0.15(0.02) 0.15(0.02) 0.15(0.02) 0.473 
HDL3 (ratio) 1.32(0.19)a 1.28(0.20)a 1.24(0.21)b 0.022 
LCAT Mass     
HDL2 (µg/L) 1220(658) 1021(689) 1139(686) 0.202 
HDL3 (µg/L) 4941(1705) 4493(1290) 4840(1668) 0.229 
Results expressed as mean(SD) or as geometric mean(interquartile range) if not normally distributed. Similar 
superscript letters indicate no differences between groups, different superscript letters indicate differences 
between groups (significance set at p≤0.05). 
CVD; cardiovascular disease: LCAT; lecithin cholesteryl acyl transferase: HDL; high density lipoprotein. 
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Table 4. Multivariate analysis of CVD risk factors with change in risk reflected by odds ratios, confidence intervals and P values 
Covariate Odds ratio(CI); P value 
Any CVD vs No CVD 
Odds ratio(CI); P value 
Significant CVD vs No CVD 
Odds ratio(CI); P value 
Significant CVD vs No or mild CVD 
Gender 
(male compared to female) 
9.06 (4.22-19.5); <1x10-5 11.9 (4.41-32.2); <1x10-5 5.89 (2.60-13.4); <1x10-5 
Age 
(per year increase) 
1.12 (1.07-1.16); <1x10-5 1.16 (1.10-1.21); <1x10-5 1.14 (1.09-1.19); <1x10-5 
SAA-HDL3 
(per 10 fold increase) 
1.71 (0.47-6.22); 0.41 5.85 (1.33-25.7); 0.02 5.91 (1.54-22.7); 0.01 
Serum-SAA 
(per 10 fold increase) 
1.70 (0.44-6.54); 0.44 1.44 (0.30-6.95); 0.65 0.86 (0.21-3.52); 0.84 
CRP 1.00 (0.83-1.21); 0.99 1.04 (0.84-1.29); 0.74 1.08 (0.89-1.31); 0.43 
CI: confidence interval. Gender, age, HDL3-SAA and CRP were added as covariates to the regression model. 
Change in risk is when we compared any CVD and significant CVD with no CVD or no or mild CVD  
 
